CD16+ NK Cell Expansion Through Pre-Differentiation Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to produce large numbers of fully functional Natural Killer (NK) cells, particularly CD16+ NK cells, for therapeutic use, as they often result in limited expansion and reduced functionality, and current therapies like cytokine enhancement and NK cell adoptive transfer are not effective.
Innovation Solution
An ex vivo method involving a pre-differentiation stage for hematopoietic progenitor cells (HPCs) using Notch ligands and REV-ERB inhibition to enhance CD16 expression, without introducing exogenous genetic elements, optimizing the duration of this stage to maximize CD16+ NK cell production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cytokine enhancement methods are used to increase NK cell numbers, then the quantity of NK cells is improved, but the functionality of NK cells deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-differentiating hematopoietic progenitor cells in a specialized medium containing Notch ligands and REV-ERB inhibitors before NK cell expansion. This pre-differentiation step prepares the cells with enhanced CD16 expression and functional characteristics, ensuring that when NK cells are subsequently expanded, they maintain high functionality while achieving large numbers. The preliminary conditioning of progenitor cells resolves the contradiction by establishing functional competence before quantity expansion is pursued.
Solution Approach 2:
The patent employs parameter changes by modifying the differentiation medium composition with specific Notch ligands (DLL4, Jagged1) and REV-ERB inhibitors (SR8278, GSK1362), and by controlling the duration of pre-differentiation (2-8 days). These parameter changes in the culture conditions fundamentally alter the developmental trajectory of progenitor cells, producing NK cells with enhanced CD16 expression and superior ADCC function while maintaining expandability, thus resolving the quantity-functionality trade-off.
2Quantity of substance
If NK cells are expanded using existing methods, then the quantity of NK cells is increased, but the proportion of CD16+ NK cells deteriorates
Solution Approach 1:
The patent applies preliminary action by implementing a pre-differentiation stage (2-8 days) in a specialized medium containing Notch ligands and REV-ERB inhibitors before NK cell expansion. This preliminary step programs the progenitor cells to develop enhanced CD16 expression, ensuring that the resulting expanded NK cell population maintains a high proportion of CD16+ cells. The preliminary conditioning resolves the contradiction by establishing the desired cell phenotype before expansion dilutes it.
Solution Approach 2:
The patent employs parameter changes by introducing specific culture conditions during pre-differentiation: Notch ligands (DLL4, Jagged1) at defined concentrations, REV-ERB inhibitors (SR8278, GSK1362), and controlling the pre-differentiation duration (2-8 days). These parameter changes fundamentally alter the differentiation trajectory to preferentially generate CD16+ NK cells, which then maintain this phenotype through subsequent expansion, resolving the contradiction between quantity and CD16+ proportion.
3Manufacturing precision
If a pre-differentiation stage is extended to maximize CD16+ NK cell production, then the proportion of CD16+ NK cells is improved, but the production time deteriorates
Solution Approach 1:
The patent applies dynamics by optimizing the pre-differentiation duration to a specific window (2-8 days) rather than using a fixed extended period. This dynamic optimization identifies the precise time point where CD16+ NK cell proportion is maximized while avoiding the diminishing returns and potential negative effects of overly prolonged culture. The dynamic approach resolves the contradiction by finding the optimal balance point in time.
4Reliability
If exogenous genetic elements are introduced to enhance NK cell function, then the functionality is improved, but the safety and complexity deteriorates
Solution Approach 1:
The patent applies self-service by using naturally occurring molecular pathways (Notch signaling and REV-ERB regulation) that are endogenous to the cells. Instead of introducing exogenous genetic elements, the method harnesses the cell's own biological machinery to achieve enhanced CD16 expression and function. This self-service approach resolves the contradiction by achieving functionality enhancement through the cell's inherent mechanisms, avoiding the safety and complexity issues of genetic modification.
Data Source
AI summary
This invention relates to expanded Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to increasing the number of CD16+ NK cells within expanded NK cell populations without the need for exogenous gene expression.